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Abstract
With the aging of western society the contribution to
morbidity of diseases of the elderly, such as dementia,
will increase exponentially. Thorough preventative and
curative strategies are needed to constrain the increas-
ing prevalence of these disabling diseases. Better under-
standing of the pathogenesis of disease will enable
development of therapy, prevention and the identifica-
tion of high-risk groups in the population. Here, we
review the genetic epidemiology of Alzheimer’s disease,
the most common cause of dementia in the western
world. The search for genetic risk factors, though far
from completed, has been of major importance for un-
derstanding the pathogenesis of Alzheimer’s disease.
Although effective therapy is still awaited, these findings
have led to new avenues for the development of drugs.
Copyright © 2002 S. Karger AG, Basel
Introduction
Although in the past century major progress has been
made in unravelling the genetics of Alzheimer’s disease
(AD), many questions remain to be answered. The de-
bates about its pathogenesis, diagnosis, therapy and pre-
vention have not been settled yet. It is clear that AD is a
complex multifactorial disorder. A great number of possi-
ble genetic risk factors have been investigated, but for
most of these no clear association has been found [1]. The
search for genetic risk factors has yielded three genes
(amyloid precursor protein [2–5], presenilin-1 [6–10] and
presenilin-2 genes [11, 12]) in which mutations were
found which result in rare autosomal dominant forms of
AD. One susceptibility gene (apolipoprotein E gene) has
been identified which is a risk factor in the general popu-
lation.
In this paper the prevalence and risk factors for AD are
reviewed. The emphasis will be on the genes known to be
involved in AD, their role in understanding the develop-
ment of the disease, and their implications for diagnosis
and clinical counselling.
Clinical Epidemiological Aspects of AD
Diagnosis and Prognosis
AD is the most common cause of dementia in the west-
ern world. The disease is clinically characterized by insid-
ious onset and slow progression of cognitive decline. Most
frequently, loss of short-term memory and impaired im-
printing of new information are the presenting symptoms
of AD. During the course of the disease, symptoms may
further include disturbance of speech, poor judgment,
personality change and deterioration of visuospatial
skills, with preserved level of consciousness. Patients
gradually lose the ability to be self-supportive, and even-
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tually they will become bedridden. Death usually occurs
due to complications of immobility and malnutrition
[13]. The average duration of AD is 8–10 years, although
at old age survival may be shorter. Available therapeutic
strategies (cholinesterase inhibitors) are not curative, but
may halt the process of decline for half a year to 2 years in
the early stages of the disease in a small number of
patients [14].
The diagnosis is based on clinical examination and
neuropsychological testing. These should yield no clues
for systemic or other brain diseases capable of causing
dementia, such as vascular dementia and subcortical de-
mentia (NINCDS-ADRDA) [15]. Although the precision
of the diagnosis has improved considerably with improve-
ment of neuropsychological tests and neuroimaging, dur-
ing life only a probable diagnosis can be made, with an
accuracy of 80–90%. The definite diagnosis of AD is
always based on histopathological findings in the brain
[16]: neuritic plaques, neurofibrillary tangles and loss of
neurons in hippocampus and cerebral cortex.
The neuritic plaques are composed of aggregations of
ß-amyloid, which are surrounded by dystrophic den-
drites, microglia and astrocytes. These plaques are located
preferentially in limbic and association cortices of the
brain, areas important for memory and cognition.
Neurofibrillary tangles consist of intraneuronal aggre-
gations of hyperphosphorylated tau. Tau is a protein that
is normally present in adult human brain, where it exerts
its function through stabilizing microtubules, which are
essential for cell shape and support and intraneuronal
transport. Hyperphosphorylated tau destabilizes the mi-
crotubule network within neurons. Due to subsequent
neuronal dysfunction and deficits in neurotransmitters,
normal brain function is impaired [17].
Prevalence of AD
The number of patients affected with AD (prevalence
of disease) is remarkably stable in western society. The
major determinant of the prevalence of disease is age.
Less than 1% of the people aged 70 years or younger is
affected with AD. But with each 5 years’ increase in age
the prevalence of AD doubles, until by age 90 years up to
30% is affected [18]. A large European follow-up study
has shown that, especially at older age, women are more
often affected than men [19, 20].
Although AD is considered to be a disease of the elder-
ly, there are patients in whom first symptoms of AD may
be present as early as at age 35 years. Frequently, a
distinction is made between ‘early-onset Alzheimer’s
disease’ (EOAD) and ‘late-onset Alzheimer’s disease’
(LOAD). The distinction is arbitrary, since clinical and
pathological features are very similar in both groups. Age
criteria for EOAD vary widely, but usually, when the age
at onset of the disease is before 65 years of age, a patient
will be diagnosed with EOAD [1].
Given its strong association with age, AD will be an
increasing health care problem in the next decades. With
the aging of western society, the number of patients is
expected to increase exponentially. By the year 2025, over
22 million patients with dementia are expected around
the world [21].
Risk Factors
AD has a complex etiology. Research in the past centu-
ry has focused on many putative environmental factors
that may either increase or decrease the risk of AD. These
included age, smoking, maternal age at birth, head trau-
ma, depression, thyroid disease, anti-inflammatory drugs,
estrogen replacement therapy, alcohol, occupational ex-
posure, aluminum, education and diet [22]. Findings
regarding these risk factors have been inconsistent. Only
increasing age and genetic predisposition are consistently
correlated with the disease [1].
Perhaps most interesting from an epidemiological per-
spective is the finding that studies on vascular risk factors
such as hypertension, diabetes mellitus, atherosclerosis,
and high cholesterol have yielded promising results,
showing an up to 2 times increased risk for AD [23–32].
The mechanism through which these vascular factors are
associated with AD remains to be elucidated. It has been
argued that these factors may be a primary cause of AD
pathology [33]. An alternative explanation may be that
vascular pathology is not a primary cause of AD, but rath-
er that it accelerates the primary neurodegenerative pro-
cess.
The findings of the relationship between vascular pa-
thology and AD are in line with cross-cultural observa-
tions by Hendrie et al. [34]. They recently published
results on differences in age-standardized annual inci-
dence rates of AD in an industrialized versus a nonindus-
trialized country. A possible explanation for the decreased
rate in the nonindustrialized country is the lower preva-
lence of cardiovascular disease in the nonindustrialized
population. However, also differences in genetic makeup
between populations may partly explain these findings.
As discussed in the next chapter, genetic susceptibility is,
in addition to increased age, the most important determi-
nant of AD.
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Genetics of AD
Familial Aggregation
As opposed to the difficulties encountered in finding
environmental risk factors for AD, the genetic component
of the disease has long been evident. Epidemiological
studies have clearly shown that AD aggregates within
families [35]. First-degree relatives of AD patients have a
3.5 times increased risk of developing AD. The relative
risk increases with a decrease in the age at onset of the
affected proband. In relatives of patients with an onset
before age 70 years the risk of having AD is increased over
4 times [35]. Concordance rates of up to 80% have been
found in monozygotic twins. In dizygotic twins concor-
dance rates were 35% [36].
In few families an autosomal dominant pattern of
inheritance can be recognized. A segregation analysis sug-
gested an autosomal dominant model in less than 1% of
198 families with EOAD [37]. In LOAD, it is difficult to
make a distinction between a dominant, recessive or addi-
tive model of inheritance [38]. In the majority of patients
the etiology appears to fit a multifactorial model in which
multiple genes and environmental factors interact [1].
Genes Involved in AD
Research on genetic determinants initially focused on
families with an autosomal dominant pattern of inheri-
tance. The first dominant mutation was found in the gene
encoding the amyloid precursor protein (APP) on chro-
mosome 21 [2–5]. Up until now, 32 families are known
around the world with EOAD due to a dominant APP
mutation (http://molgen-www.uia.ac.be/ADMutations/).
Besides APP, two homologous genes were identified,
presenilin-1 (PSEN-1) at chromosome 14 and presenilin-2
(PSEN-2) at chromosome 1q31-q42, which account for
families segregating AD as an autosomal dominant trait
as well. So far, more than 80 mutations of the PSEN-1
gene have been identified [6–10] (http://molgen-
www.uia.ac.be/ADMutations/). Six mutations in PSEN-2
are described [11, 12] (http://molgen-www.uia.ac.be/AD-
Mutations/).
Frequency estimates of these mutations in EOAD pa-
tients are highly variable, ranging from less than 1 to 50%
[e.g. 39–41]. Differences might be due to more or less
stringent diagnostic criteria in the population under study
(e.g. probable vs. autopsy-confirmed AD), different maxi-
mum age when considering early onset, and selection of
study populations. A study population derived from a
highly specialized neurological center is more likely to
have an overrepresentation of cases with high familial
aggregation. However, in a population-based sample [41]
APP mutations were found in only 0.5% of all EOAD
patients and accounted for only 0.005% of AD in the gen-
eral population. Although mutations in PSEN-1 are more
common, they still only accounted for 6.5% of all EOAD
patients (i.e. 0.065% of AD in the general population).
Mutations in PSEN-2 were seen in less than 1% of all
EOAD patients, and less than 0.01% of the general popu-
lation. Together, dominant mutations in APP, PSEN-1
and PSEN-2 occurred in only 0.075% of AD patients at
the population level [41, 42]. Although these genes have a
minor impact in the general population, for the individual
carrier the risk is extremely high. Almost all carriers of
these mutations express the disease. As EOAD is rare, risk
estimates for carriers of these mutations approximate
infinity.
In addition to the three autosomal dominant genes, a
fourth gene (apolipoprotein E, APOE) was identified
which is localized on chromosome 19 and has three com-
mon alleles coding for three different isoforms of the pro-
tein. The allele frequencies of this gene (APOE) are 0.08
for APOE*2, 0.77 for APOE*3 and 0.15 for APOE*4 in
populations of European ancestry [42]. APOE*4 is strong-
ly associated with LOAD [43, 44] and EOAD [45]. Sub-
jects homozygous for APOE*4 have an almost 15 times
increased risk of developing AD, but 50% will not develop
the disease [46]. Subjects with only one APOE*4 allele
have a moderately increased risk (around 3 times) [47].
Although risks are moderately increased for APOE*4 for
the individual carrier, due to the fact that the allele is
common APOE*4 may explain 17% of the occurrence of
AD in the general population [42]. Homozygosity for
APOE*4 contributes less than 2% to AD because of low
prevalence of this genotype (0.0225). It is suggested that
APOE*4 regulates when rather than if the disease occurs
[47, 48]. Due to a relatively earlier onset of LOAD in
those homozygous for APOE*4, the influence of compet-
ing morbidity and mortality will be less, thereby enhanc-
ing the association between APOE*4 homozygosity and
LOAD.
Genes and the Pathogenesis of AD
The discovery of mutations in the genes involved in
AD has been of great importance for the understanding of
the biological mechanisms underlying AD. All causal mu-
tations affect the normal metabolism of ß-amyloid, sug-
gesting that ß-amyloid constitutes a central event in the
pathogenesis of AD. ß-Amyloid, or Aß, is a peptide
present under physiological circumstances in healthy sub-
jects. Due to a mutation in any of the known AD genes,
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the equilibrium between production and clearance of Aß
gets disturbed, resulting in accumulation of Aß in the
brain. Amyloid fibrils are formed and subsequently de-
posited into plaques. At present, the most likely hypothe-
sis is that at first diffuse plaques are formed. These
plaques can also be seen in healthy subjects. In AD
patients several of these plaques may evolve into ‘mature’
neuritic plaques containing fibrillar aggregates, damaged
neurons and activated glial cells in a cascade of pathologi-
cal processes, eventually leading to profuse neuronal loss
[49–57].
APP is a transmembrane protein that is widely ex-
pressed on the cell surface. Its functional properties are
not clearly defined, but range from repair of vascular inju-
ry to mediation of growth and adhesion of neural and
nonneural cells [53]. Recently it has been suggested that
APP has a function in the regulation of nuclear transcrip-
tion [58]. APP is cleaved into Aß. The different mutations
that have been found so far in the gene coding for APP are
located at or near cleavage sites [40]. By abnormal cleav-
age of APP larger amounts of a longer version of Aß are
produced, called Aß42 [59–62]. This longer version is
more amyloidogenic and therefore aggregates more easily
into plaques [63]. There is increasing evidence that Aß42
may play a crucial role in the pathogenesis of AD.
The function of the presenilin proteins is unclear, but it
has been shown that mutations in PSEN also lead to
altered APP processing. Aß42 levels are raised in brain,
plasma and fibroblasts [64] of carriers of a PSEN muta-
tion. Furthermore, in experiments with PSEN-transgenic
mice and transfected cells higher Aß42 levels are found as
well [65–68].
In sporadic LOAD the pattern of Aß accumulation is
less evident. It has been suggested that accumulation is
rather the result of impaired clearance of Aß than of
increased synthesis [57]. In carriers of the APOE*4 allele,
the predominant genetic risk factor in sporadic AD,
APOE has increased affinity for Aß and Aß aggregates.
Although the precise mechanism has not yet been eluci-
dated, APOE*4 is suggested to facilitate Aß aggregation or
to inhibit the elimination of the fibrillar aggregates [44,
69, 70].
Although a body of genetic evidence supports the Aß
cascade hypothesis and although it is the most compre-
hensive theory so far, the debates on this hypothesis have
not been settled yet [50, 57, 71, 72]. Disagreement ranges
from details within the Aß hypothesis (e.g. that not the
total amount of Aß is important but rather the relative
proportion of Aß42) to the reverse hypothesis that Aß
accumulation is a compensatory mechanism to aging [73].
A finding difficult to explain has been that amyloid depo-
sition does not seem to correlate very well with cognitive
decline [50]. However, recent findings may have settled
this argument by showing that Aß plasma levels are ele-
vated early in the course of the disease and are strongly
related to cognitive decline, a finding in favor of the Aß
cascade hypothesis [74, 75].
While the Aß hypothesis is being refined other patho-
genic models are considered as plausible. These include
hypotheses on the involvement of tau [76], on neuroplas-
ticity [77], aging [72], oxidative stress [78], impaired cere-
bromicrovascular perfusion [79], inflammation [80] and
lipid homeostasis [70].
Genetic Counselling and Risk Prediction
The identification of genes involved in AD has been a
major breakthrough. Yet there is ongoing debate on their
use in clinical counselling.
Given the fact that APP, PSEN-1 and PSEN-2 muta-
tions have a virtually complete penetrance and that these
mutations are not found in healthy age-matched subjects,
one might argue that these mutations are useful for risk
prediction and genetic counselling. But the known muta-
tions are only present in a minority of cases. Although
mutations can be found frequently in patient populations
from highly specialized centers due to selection bias [81],
these mutations are rare in the general population. Thus,
for risk prediction and counselling, the absence of a
known mutation should not be conclusive. Even if the
underlying mutation is known in a family with an autoso-
mal dominant form of AD, there is a strong argument
against screening relatives at risk, because curative thera-
py and prevention are not yet at hand. An argument in
favor of screening relatives at risk and those that already
have dementia without a definite diagnosis might be to
take away incertitude and allow for future plans, but
screening should always be preceded by thorough coun-
selling, taking into account ethical considerations.
Because of their low frequency, the mutations are not
useful as a diagnostic tool for patients with early onset
symptoms of dementia [39].
Also the use of APOE is limited in the clinical practice.
APOE*4 increases the susceptibility to AD, but the in-
crease in risk is modest, especially in the heterozygous car-
riers of the APOE*4 allele. As only 50% of the AD patients
carry APOE*4 and a substantial number of patients with
other dementias show similar frequencies, APOE*4 is not
suitable for diagnostic purposes [82]. Even for subjects
homozygous for the APOE*4 allele there is still a 50%
chance not to develop the disease [46]. Thus despite the
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fact that APOE is a more important determinant of AD in
the general population than APP, PSEN-1 and PSEN-2,
APOE is not suitable for risk prediction and counselling.
Considerations
The discovery of the dominant mutations in the APP,
PSEN-1 and PSEN-2 genes in the families with autosomal
dominant EOAD explains only a minor proportion of the
disease in the general population. The clinical use is lim-
ited and awaits therapy and prevention. Nevertheless,
genetic research has made a significant contribution to
understanding the pathogenesis of the disease, even in
sporadic patients. Genetic evidence is pointing towards a
central role for amyloid metabolism in the etiology of AD.
Due to the genetic evidence towards Aß research focusing
on Aß has expanded impressively. Recently, promising
evidence has been found in vaccination strategies with Aß
in mice, decreasing formation of Aß [83] and enhancing
cognition in mouse models [84–86]. Verification of these
findings in man, combined with useful biomarkers, will
be of tremendous importance in the prevention of this
disabling disease. Recently, trials in humans were halted
because of major side effects.
Meanwhile, other genetic and environmental factors
should still be considered to fill the lacunae in our knowl-
edge of AD. Better understanding of the neuropathologi-
cal mechanisms underlying AD, whether based on genetic
findings or on results of other kinds of scientific research,
will without a doubt aid future therapeutic and preventive
strategies.
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